The agency recommends manufacturers update their vaccines to target the JN.1 strain. At the same time, HHS head Robert F.

The FDA has placed a clinical hold on the study while Rocket works with trial monitors and experts to investigate the cause ...

The startup is the latest beneficiary of investors’ appetite for protein-degrading technology, which offers a way to reach ...

The advisory committee, which met after the agency rolled out new vaccine guidelines, said companies should tailor their ...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

Still, the therapies’ modest benefit as a maintenance therapy points to how better treatments are needed for small cell lung ...

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body ...

Agency drug reviewers had questioned patient risk criteria and the efficacy endpoint used in a key trial supporting J&J's ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

ReproNovo has licensed rights to two drugs from Mereo BioPharma and ObsEva that it thinks could address fertility issues in ...

The agency will now require randomized, controlled data before approving new COVID shots for healthy children and adults, ...

The announcement, which followed the FDA setting new guidelines on COVID vaccine approvals, erased the stock’s gains from ...